PMID- 31564971
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - ERRalpha is an aggressive factor in lung adenocarcinoma indicating poor prognostic 
      outcomes.
PG  - 8111-8123
LID - 10.2147/CMAR.S204732 [doi]
AB  - PURPOSE: Lung cancer is one of the most life-threatening cancer worldwide with 
      poor prognosis attributed to the lack of early diagnosis and proper therapy. The 
      estrogen-related receptor alpha (ERRalpha) is a multifunctional protein not limited 
      to bind ligands and has been reported to be associated with numerous cancers. 
      This study aimed to investigate the potential role of ERRalpha in lung cancer and to 
      provide a novel perspective for lung cancer early diagnosis, targeted therapy, 
      and prognosis assessment. METHODS: The correlation between ERRalpha mRNA expression 
      and survival time of the online clinical data about lung cancer was analyzed by 
      using Kaplan-Meier (KM) plotter. A mouse model of lung adenocarcinoma (LUAD) was 
      constructed to detect the expression level of ERRalpha in tumor tissues. 
      ERRalpha-knockdown LUAD cells were generated and the impacts of ERRalpha on cell 
      proliferation, invasion, and metastasis were further analyzed. Cancerous and 
      paracancerous tissues were collected to semi-quantitative the levels of ERRalpha in 
      LUAD clinical samples (n=88), combined with clinical information for prognostic 
      analysis. RESULTS: The KM plotter analysis suggested that ERRalpha is correlated with 
      poor prognosis in LUAD (n=720) rather than in lung squamous cell carcinoma (LSCC) 
      (n=524). ERRalpha is also upregulated in tumor tissues obtained from LUAD model mice. 
      Quantitative analysis suggested an abnormal elevation of ERRalpha in LUAD cells 
      rather than in LSCC cells. The results demonstrated that downregulation of ERRalpha 
      impairs proliferation, invasion and migration abilities (P<0.01). The prognostic 
      analysis showed that the overexpressed ERRalpha in LUAD was positively correlated 
      with low survival rates (HR=1.597). The results indicate that the death risk of 
      ERRalpha high expression is 1.597 times higher than ERRalpha low level in LUAD patients. 
      CONCLUSION: In summary, our findings suggest that ERRalpha is a potential aggressive 
      factor of LUAD which implies poor prognosis.
CI  - (c) 2019 Li et al.
FAU - Li, Ping
AU  - Li P
AD  - Biobank, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen 
      University, Shenzhen 518035, People's Republic of China.
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
AD  - Department of Toxicology, Shenzhen Center for Disease Control and Prevention, 
      Shenzhen 518035, People's Republic of China.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Thoracic Surgery, The Shenzhen People's Hospital, Shenzhen 518020, 
      People's Republic of China.
FAU - Wu, Desheng
AU  - Wu D
AD  - Department of Toxicology, Shenzhen Center for Disease Control and Prevention, 
      Shenzhen 518035, People's Republic of China.
FAU - Ren, Xiaohu
AU  - Ren X
AD  - Department of Toxicology, Shenzhen Center for Disease Control and Prevention, 
      Shenzhen 518035, People's Republic of China.
FAU - Wu, Wen
AU  - Wu W
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
AD  - Department of Toxicology, Shenzhen Center for Disease Control and Prevention, 
      Shenzhen 518035, People's Republic of China.
FAU - Zuo, Ran
AU  - Zuo R
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
FAU - Zeng, Qingbo
AU  - Zeng Q
AD  - Department of Toxicology, Shenzhen Center for Disease Control and Prevention, 
      Shenzhen 518035, People's Republic of China.
FAU - Wang, Bingyu
AU  - Wang B
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
FAU - He, Xi
AU  - He X
AD  - Biobank, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen 
      University, Shenzhen 518035, People's Republic of China.
FAU - Yuan, Jianhui
AU  - Yuan J
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
AD  - Department of Occupational Health, Shenzhen Nanshan District Center for Disease 
      Control and Prevention, Shenzhen 518054, People's Republic of China.
FAU - Xie, Ni
AU  - Xie N
AD  - Biobank, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen 
      University, Shenzhen 518035, People's Republic of China.
AD  - Department of Medicine, University of South China, Hengyang 421001, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190902
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6730612
OTO - NOTNLM
OT  - ERRalpha
OT  - estrogen-related receptor alpha
OT  - lung adenocarcinoma
OT  - metastasis
OT  - migration
OT  - poor prognosis
OT  - proliferation
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/10/01 06:00
MHDA- 2019/10/01 06:01
PMCR- 2019/09/02
CRDT- 2019/10/01 06:00
PHST- 2019/02/10 00:00 [received]
PHST- 2019/07/28 00:00 [accepted]
PHST- 2019/10/01 06:00 [entrez]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2019/10/01 06:01 [medline]
PHST- 2019/09/02 00:00 [pmc-release]
AID - 204732 [pii]
AID - 10.2147/CMAR.S204732 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Sep 2;11:8111-8123. doi: 10.2147/CMAR.S204732. eCollection 
      2019.